Pipeline Therapeutics

Rob Leland Shaver, Michelle A. Lowes, Noah Goldfarb

Research output: Chapter in Book/Report/Conference proceedingChapter


Investigation into therapeutics for hidradenitis suppurativa (HS) has increased over the past two decades. As more is understood about HS pathogenesis, the number of drug targets has steadily risen. Neutrophils as well as the complement pathway have both been shown to contribute to HS pathogenesis and have become the focus of several ongoing clinical trials. Similarly, cytokines such as IL-17, IL-12/23, and IL1-α/β are being targeted for their suspected role in HS pathogenesis. Trials are also underway for small molecule inhibitors of the JAK/STAT pathway as well as anti-hormonal therapies and CD40 blockade. Beyond pharmaceuticals, there are also several surgical, procedural, and complementary and alternative practices currently being investigated. The future of HS looks bright as investigators continue to innovate and expand on HS management.

Original languageEnglish (US)
Title of host publicationA Comprehensive Guide to Hidradenitis Suppurativa
Number of pages11
ISBN (Electronic)9780323777247
ISBN (Print)9780323777254
StatePublished - Jan 1 2022

Bibliographical note

Publisher Copyright:
© 2022 Elsevier Inc. All rights reserved.


  • clinical trials
  • Hidradenitis
  • pipeline therapeutics


Dive into the research topics of 'Pipeline Therapeutics'. Together they form a unique fingerprint.

Cite this